- Home
- SORA vs ATRA Comparison
SORA vs ATRA Comparison
Compare SORA & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SORA | ATRA |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | Hong Kong | United States |
| Employees | 7 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.5M | 38.9M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SORA | ATRA |
|---|---|---|
| Price | $1.85 | $5.08 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 6.3K | ★ 284.3K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.07 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.57 | $3.92 |
| 52 Week High | $10.27 | $19.15 |
Technical Indicators
Market Signals| Indicator | SORA | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 44.08 |
| Support Level | $1.76 | $4.27 |
| Resistance Level | $3.08 | $5.80 |
| Average True Range (ATR) | 0.11 | 0.77 |
| MACD | 0.03 | 0.18 |
| Stochastic Oscillator | 21.79 | 16.61 |
Price Performance
Historical ComparisonAbout SORA Top Win International Limited Ordinary Shares
AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).